Phreesia vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 40)
Phreesia logo

Phreesia

EmergingHealthcare

Patient Intake

NYSE-listed (PHR) patient intake platform digitizing check-in for 4,000+ practices at $383M revenue; pharma-funded activation programs competing with Epic and Clearwave for healthcare front-office engagement.

AI VisibilityBeta
Overall Score
C40
Category Rank
#379 of 596
AI Consensus
78%
Trend
up
Per Platform
ChatGPT
38
Perplexity
35
Gemini
44

About

Phreesia is a Raleigh, North Carolina-based patient intake and engagement platform — listed on NYSE (NYSE: PHR) — providing healthcare practices, health systems, and pharmaceutical companies with digital tools for patient registration, insurance verification, payment collection, clinical pre-screening, and patient activation. Founded in 2005 by Chaim Indig and Evan Roberts and generating $383 million in revenue in fiscal year 2025 (ending January 2025), Phreesia serves 4,000+ healthcare practices and health systems with the patient-facing digital infrastructure that replaces paper clipboards and manual front-desk registration.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

40
Overall Score
90
#379
Category Rank
#2
78
AI Consensus
83
up
Trend
stable
38
ChatGPT
92
35
Perplexity
93
44
Gemini
89
42
Claude
96
38
Grok
95

Key Details

Category
Patient Intake
Enterprise
Tier
Emerging
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Phreesia
Patient Intake

Integrations

Only Moderna
Phreesia is classified as company. Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.